Small caps round-up: Angel Biotech, Alliance Pharma, Fastjet

Angel Biotech has seen a continuation of the 'very difficult' market conditions since mid-September, with funding constraints of clients forcing delays and changed priorities with a number of potential customers. However, the group is currently seeing an upturn in the volume of enquiries and bids, especially in areas opened up by the group's wider commercial offering in biomedical collagen. "Success in the completion of the tasks and delivery of earnings is fundamental and the board and the group's management are clear on what is expected of them," the firm said.

Angel Biotech has seen a continuation of the 'very difficult' market conditions since mid-September, with funding constraints of clients forcing delays and changed priorities with a number of potential customers. However, the group is currently seeing an upturn in the volume of enquiries and bids, especially in areas opened up by the group's wider commercial offering in biomedical collagen. "Success in the completion of the tasks and delivery of earnings is fundamental and the board and the group's management are clear on what is expected of them," the firm said.

Alliance Pharma, a speciality pharmaceutical company, has said its wholly owned subsidiary, Alliance Pharmaceuticals, has acquired Opus Group Holdings for £8.0m plus the net asset value of Opus at completion (estimated at £1.5m). The Opus group sells products for stoma care, including skin creams and cleansers, in the UK and Ireland. In the year ended March 31st Opus delivered turnover of £3.8m and pre-tax profit of £2.1m. The consideration is being funded from existing cash and bank facilities.

FastJet, Africa's first pan African low cost airline, has signed a maintenance contract with a leading aircraft maintenance company and further strengthened its management team ahead of the airline's planned launch next month. FastJet has signed operating lease agreements with Volito Aviation for two Airbus A319s and will take delivery of the aircraft in November.

NR

Recommended

Britain’s ten most-hated shares – w/e 9 August
Stocks and shares

Britain’s ten most-hated shares – w/e 9 August

Rupert Hargreaves looks at Britain's ten most-hated shares, and what short-sellers are looking at now.
10 Aug 2022
Aviva: One for income investors to tuck away
Share tips

Aviva: One for income investors to tuck away

Insurance giant Aviva is one of the highest yielding stocks in the FTSE 100 – and it’s cheap, too, making it a tempting target for income investors. R…
10 Aug 2022
Director dealings w/e 5 August: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 5 August: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
9 Aug 2022
Britain’s most-bought shares w/e 5 August
Stocks and shares

Britain’s most-bought shares w/e 5 August

A look at Britain’s most-bought shares as of 5 August, providing an insight into how investors are thinking and where opportunities may lie.
9 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Fear of missing out – what should investors do now?
Investment strategy

Fear of missing out – what should investors do now?

Markets have rallied from their mid-June lows. But if you missed out, as most investors did, what should you do now? Max King explains.
8 Aug 2022